ArticleCureus2026
Immunogenic Tumor Cell Death Induced by Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer: An Immunohistochemical Analysis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate immunogenic cell death (ICD) induced by platinum-based neoadjuvant chemotherapy (NAC) and its impact on survival outcomes in patients with muscle-invasive bladder cancer (MIBC) who underwent radical cystectomy (RC).
methodsThis study included 45 patients with MIBC who underwent RC with (n = 25) or without NAC (n = 20). Induction of ICD in MIBC was assessed by comparing immunohistochemical analyses of two ICD-related proteins, high-mobility group box 1 (HMGB1) and calreticulin, between transurethral resection (TUR) and matched RC specimens. Clinicopathologic data, including the upregulation of ICD-related proteins, were correlated with survival outcomes after RC.
resultsUpregulation of HMGB1 and calreticulin from TUR to matched RC specimens was observed in 11 (44%) and 12 (48%) of 25 NAC-treated patients, respectively, whereas it was detected in only two (8%) and one (4%) patients without NAC (P = 0.03 and P = 0.01, respectively). Upregulation of HMGB1 was significantly associated with longer cancer-specific survival (CSS) and overall survival (P < 0.01 and P = 0.02, respectively). Upregulation of HMGB1 and histological subtype (P = 0.03 and P = 0.05, respectively) were independent prognostic factors for CSS. Furthermore, among NAC-treated patients with recurrent disease, upregulation of HMGB1 tended to correlate with a better response to subsequent immune checkpoint inhibitor therapy and longer survival (P = 0.07).
conclusionsOur findings suggest that platinum-based NAC induces ICD in MIBC. Upregulation of HMGB1 may serve as a marker of chemotherapy-induced ICD and as a potential prognostic biomarker after RC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.